More than a decade has passed since it was unintentionally discovered that grapefruit juice interacts with certain drugs. The coadministration of these drugs with grapefruit juice can markedly elevate drug bioavailability, and can alter pharmacokinetic and pharmacodynamic parameters of the drug. The predominant mechanism for this interaction is the inhibition of cytochrome P-450 3A4 in the small intestine, resulting in a significant reduction of drug presystemic metabolism. An additional mechanism is, presumably, the inhibition of P-glycoprotein, a transporter that carries drug from the enterocyte back to the gut lumen, resulting in a further increase in the fraction of drug absorbed. Some calcium channel antagonists, benzodiazepines, HMG-CoA reductase inhibitors and cyclosporine are the most affected drugs. A single exposure to one glass of the juice can usually produce the maximal magnitude of the interaction. The data available so far, concerning this interaction and its clinical implications, are reviewed in this article. It is likely that more information regarding this interaction will accumulate in the future, and awareness of such is necessary for achieving optimal drug therapy.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Scientific Reports Open Access 20 January 2022
Pharmacokinetic parameters of ifosfamide in mouse pre-administered with grapefruit juice or naringin
Scientific Reports Open Access 12 November 2019
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Bailey DG, Arnold JM, Bend JR, Tran LT & Spence JD (1995): Grapefruit juice–felodipine interaction: reproducibility and characterization with the extended release drug formulation. Br. J. Clin. Pharmacol. 40, 135–140.
Bailey DG, Arnold JM, Munoz C & Spence JD (1993a): Grapefruit juice–felodipine interaction: mechanism, predictability, and effect of naringin. Clin. Pharmacol. Ther. 53, 637–642.
Bailey DG, Arnold JM, Strong HA, Munoz C & Spence JD (1993b): Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics. Clin. Pharmacol. Ther. 54, 589–594.
Bailey DG, Dresser GK, Kreeft JH, Munoz C, Freeman DJ & Bend JR (2000): Grapefruit–felodipine interaction: effect of unprocessed fruit and probable active ingredients. Clin. Pharmacol. Ther. 68, 468–477.
Bailey DG, Malcolm J, Arnold O & Spence JD (1998): Grapefruit juice–drug interactions. Br. J. Clin. Pharmacol. 46, 101–110.
Bailey DG, Spence JD, Edgar B, Bayliff CD & Arnold JM (1989): Ethanol enhances the hemodynamic effects of felodipine. Clin. Invest. Med. 12, 357–362.
Bailey DG, Spence JD, Munoz C & Arnold JM (1991): Interaction of citrus juices with felodipine and nifedipine. Lancet 337, 268–269.
Benton RE, Honig PK, Zamani K, Cantilena LR & Woosley RL (1996): Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin. Pharmacol. Ther. 59, 383–388.
Bistrup C, Nielsen FT, Jeppesen UE & Dieperink H (2001): Effect of grapefruit juice on sandimmun neoral absorption among stable renal allograft recipients. Nephrol. Dial. Transplant 16, 373–377.
Bohets H, Lavrijsen K, Hendrickx J, van Houdt J, van Genechten V, Verboven P, Meuldermans W & Heykants J (2000): Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride: in vitro studies of potential co-medication interactions. Br. J. Pharmacol. 129, 1655–1667.
Brunner LJ, Pai KS, Munar MY, Lande MB, Olyaei AJ & Mowry JA (2000): Effect of grapefruit juice on cyclosporin A pharmaco-kinetics in pediatric renal transplant patients. Pediatr. Transplant. 4, 313–321.
Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR & Davies DS (1997): The cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice. Eur. J. Clin. Pharmacol. 52, 311–315.
Dresser GK, Bailey DG & Carruthers SG (2000): Grapefruit juice–felodipine interaction in the elderly. Clin. Pharmacol. Ther. 68, 28–34.
Ducharme MP, Warbasse LH & Edwards DJ (1995): Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin. Pharmacol. Ther. 57, 485–491.
Eagling VA, Profit L & Back DJ (1999): Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br. J. Clin. Pharmacol. 48, 543–552.
Edgar B, Bailey D, Bergstrand R, Johnsson G & Regardh CG (1992): Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine—and its potential clinical relevance. Eur. J. Clin. Pharmacol. 42, 313–317.
Edwards DJ, Bellevue III FH & Woster PM (1996): Identification of 6′,7′-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. Drug Metab. Dispos. 24, 1287–1290.
Edwards DJ & Bernier SM (1996): Naringin and naringenin are not the primary CYP3A inhibitors in grapefruit juice. Life Sci. 59, 1025–1030.
Fabre G, Julian B, Saint Aubert B, Joyeux H & Berger Y (1993): Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions. Drug Metab. Dispos. 21, 978–985.
Fitzsimmons ME & Collins JM (1997): Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. Drug Metab. Dispos. 25, 256–266.
Fuhr U, Maier Bruggemann A, Blume H, Muck W, Unger S, Kuhlmann J, Huschka C, Zaigler M, Rietbrock S & Staib AH (1998): Grapefruit juice increases oral nimodipine bioavailability. Int. J. Clin. Pharmacol. Ther. 36, 126–132.
Fuhr U, Muller-Peltzer H, Kern R, Lopez-Rojas P, Junemann M, Harder S & Staib A (2002): Effects of grapefruit juice and smoking on verapamil concentrations in steady state. Eur. J. Clin. Pharmacol. 58, 45–53.
Fukuda K, Guo L, Ohashi N, Yoshikawa M & Yamazoe Y (2000): Amounts and variation in grapefruit juice of the main components causing grapefruit–drug interaction. J. Chromatogr. B 741, 195–203.
Garg SK, Kumar N, Bhargava VK & Prabhakar SK (1998): Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy. Clin. Pharmacol. Ther. 64, 286–288.
Gottesman MM, Pastan I & Ambudkar SV (1996): P-glycoprotein and multidrug resistance. Curr. Opin. Genet. Dev. 6, 610–617.
Gross AS, Goh YD, Addison RS & Shenfield GM (1999): Influence of grapefruit juice on cisapride pharmacokinetics. Clin. Pharmacol. Ther. 65, 395–401.
Guo LQ, Fukuda K, Ohta T & Yamazoe Y (2000): Role of furanocoumarin derivatives on grapefruit juice-mediated inhibition of human CYP3A activity. Drug Metab. Dispos. 28, 766–771.
Hashimoto K, Shirafuji T, Sekino H, Matsuoka O, Onnagawa O, Okamoto T, Kudo S & Azuma J (1998): Interaction of citrus juices with pranidipine, a new 1,4-dihydropyridine calcium antagonist, in healthy subjects. Eur. J. Clin. Pharmacol. 54, 753–760.
He K, Iyer KR, Hayes RN, Sinz MW, Woolf TF & Hollenberg PF (1998): Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem. Res. Toxicol. 11, 252–259.
Ho PC, Ghose K, Saville D & Wanwimolruk S (2000): Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers. Eur. J. Clin. Pharmacol. 56, 693–698.
Honig PK, Wortham DC, Lazarev A & Cantilena LR (1996): Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine. J. Clin. Pharmacol. 36, 345–351.
Hukkinen SK, Varhe A, Olkkola KT & Neuvonen PJ (1995): Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. Clin. Pharmacol. Ther. 58, 127–131.
Hyland R, Roe EG, Jones BC & Smith DA (2001): Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. Br. J. Clin. Pharmacol. 51, 239–248.
Ioannides Demos LL, Christophidis N, Ryan P, Angelis P, Liolios L & McLean AJ (1997): Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases. J. Rheumatol. 24, 49–54.
Jacobsen W, Kirchner G, Hallensleben K, Mancinelli L, Deters M, Hackbarth I, Benet LZ, Sewing KF & Christians U (1999): Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab. Dispos. 27, 173–179.
Jetter A, Kinzig Schippers M, Walchner Bonjean M, Hering U, Bulitta J, Schreiner P, Sorgel F & Fuhr U (2002): Effects of grapefruit juice on the pharmacokinetics of sildenafil. Clin. Pharmacol. Ther. 71, 21–29.
Josefsson M, Zackrisson AL & Ahlner J (1996): Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers. Eur. J. Clin. Pharmacol. 51, 189–193.
Kane GC & Lipsky JJ (2000): Drug–grapefruit juice interactions. Mayo Clin. Proc. 75, 933–942.
Kantola T, Kivisto KT & Neuvonen PJ (1998): Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin. Pharmacol. Ther. 63, 397–402.
Kivisto KT, Lilja JJ, Backman JT & Neuvonen PJ (1999): Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride. Clin. Pharmacol. Ther. 66, 448–453.
Kolars JC, Awni WM, Merion RM & Watkins PB (1991): First-pass metabolism of cyclosporin by the gut. Lancet 338, 1488–1490.
Kolars JC, Schmiedlin Ren P, Schuetz JD, Fang C & Watkins PB (1992): Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J. Clin. Invest. 90, 1871–1878.
Kuhnau J (1976): The flavonoids. A class of semi-essential food components: their role in human nutrition. World Rev. Nutr. Diet. 24, 117–191.
Kupferschmidt HH, Fattinger KE, Ha HR, Follath F & Krahenbuhl S (1998): Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br. J. Clin. Pharmacol. 45, 355–359.
Kupferschmidt HH, Ha HR, Ziegler WH, Meier PJ & Krahenbuhl S (1995): Interaction between grapefruit juice and midazolam in humans. Clin. Pharmacol. Ther. 58, 20–28.
Lee AJ, Chan WK, Harralson AF, Buffum J & Bui BC (1999): The effects of grapefruit juice on sertraline metabolism: an in vitro and in vivo study. Clin. Ther. 21, 1890–1899.
Lee M & Min DI (2001): Determination of sildenafil citrate in plasma by high-performance liquid chromatography and a case for the potential interaction of grapefruit juice with sildenafil citrate. Ther. Drug Monit. 23, 21–26.
Letteron P, Descatoire V, Larrey D, Tinel M, Geneve J & Pessayre D (1986): Inactivation and induction of cytochrome P-450 by various psoralen derivatives in rats. J. Pharmacol. Exp. Ther. 238, 685–692.
Libersa CC, Brique SA, Motte KB, Caron JF, Guedon Moreau LM, Humbert L, Vincent A, Devos P & Lhermitte MA (2000): Dramatic inhibition of amiodarone metabolism induced by grapefruit juice. Br. J. Clin. Pharmacol. 49, 373–378.
Lilja JJ, Kivisto KT, Backman JT, Lamberg TS & Neuvonen PJ (1998): Grapefruit juice substantially increases plasma concentrations of buspirone. Clin. Pharmacol. Ther. 64, 655–660.
Lilja JJ, Kivisto KT, Backman JT & Neuvonen PJ (2000a): Effect of grapefruit juice dose on grapefruit juice–triazolam interaction: repeated consumption prolongs triazolam half-life. Eur. J. Clin. Pharmacol. 56, 411–415.
Lilja JJ, Kivisto KT & Neuvonen PJ (1998): Grapefruit juice–simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin. Pharmacol. Ther. 64, 477–483.
Lilja JJ, Kivisto KT & Neuvonen PJ (1999): Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin. Pharmacol. Ther. 66, 118–127.
Lilja JJ, Kivisto KT & Neuvonen PJ (2000b): Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin. Clin. Pharmacol. Ther. 68, 384–390.
Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, Brown MB, Guo W & Watkins PB (1997): Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J. Clin. Invest. 99, 2545–2553.
Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin Ren P, Brown MB, Guo W, Rossi SJ, Benet LZ & Watkins PB (1997): Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin. Pharmacol. Ther. 62, 248–260.
Lundahl J, Regardh CG, Edgar B & Johnsson G (1995): Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine in healthy subjects. Eur. J. Clin. Pharmacol. 49, 61–67.
Lundahl J, Regardh CG, Edgar B & Johnsson G (1997): Effects of grapefruit juice ingestion—pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men. Eur. J. Clin. Pharmacol. 52, 139–145.
Lundahl JU, Regardh CG, Edgar B & Johnsson G (1998): The interaction effect of grapefruit juice is maximal after the first glass. Eur. J. Clin. Pharmacol. 54, 75–81.
Michalets EL & Williams CR (2000): Drug interactions with cisapride: clinical implications. Clin. Pharmacokinet. 39, 49–75.
Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF & Hunsicker LG (1996): Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients. Transplantation 62, 123–125.
Miniscalco A, Lundahl J, Regardh CG, Edgar B & Eriksson UG (1992): Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapefruit juice. J. Pharmacol. Exp. Ther. 261, 1195–1199.
Mohri K & Uesawa Y (2001): Effects of furanocoumarin derivatives in grapefruit juice on nifedipine pharmacokinetics in rats. Pharm. Res. 18, 177–182.
Offman EM, Freeman DJ, Dresser GK, Munoz C, Bend JR & Bailey DG (2001): Red wine–cisapride interaction: comparison with grapefruit juice. Clin. Pharmacol. Ther. 70, 17–23.
Ohnishi A, Matsuo H, Yamada S, Takanaga H, Morimoto S, Shoyama Y, Ohtani H & Sawada Y (2000): Effect of furanocoumarin derivatives in grapefruit juice on the uptake of vinblastine by Caco-2 cells and on the activity of cytochrome P450 3A4. Br. J. Pharmacol. 130, 1369–1377.
Ozdemir M, Aktan Y, Boydag BS, Cingi MI & Musmul A (1998): Interaction between grapefruit juice and diazepam in humans. Eur. J. Drug Metab. Pharmacokinet. 23, 55–59.
Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD & Thummel KE (1997): Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J. Pharmacol. Exp. Ther. 283, 1552–1562.
Phang JM, Poore CM, Lopaczynska J & Yeh GC (1993): Flavonol-stimulated efflux of 7,12-dimethylbenz(a)anthracene in multidrug-resistant breast cancer cells. Cancer Res. 53, 5977–5981.
Rashid J, McKinstry C, Renwick AG, Dirnhuber M, Waller DG & George CF (1993): Quercetin, an in vitro inhibitor of CYP3A, does not contribute to the interaction between nifedipine and grapefruit juice. Br. J. Clin. Pharmacol. 36, 460–463.
Rau SE, Bend JR, Arnold MO, Tran LT, Spence JD & Bailey DG (1997): Grapefruit juice–terfenadine single-dose interaction: magnitude, mechanism, and relevance. Clin. Pharmacol. Ther. 61, 401–409.
Rogers JD, Zhao J, Liu L, Amin RD, Gagliano KD, Porras AG, Blum RA, Wilson MF, Stepanavage M & Vega JM (1999): Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Clin. Pharmacol. Ther. 66, 358–366.
Schmiedlin Ren P, Edwards DJ, Fitzsimmons ME, He K, Lown KS, Woster PM, Rahman A, Thummel KE, Fisher JM, Hollenberg PF & Watkins PB (1997): Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab. Dispos. 25, 1228–1233.
Sigusch H, Henschel L, Kraul H, Merkel U & Hoffmann A (1994): Lack of effect of grapefruit juice on diltiazem bioavailability in normal subjects. Pharmazie 49, 675–679.
Soldner A, Christians U, Susanto M, Wacher VJ, Silverman JA & Benet LZ (1999): Grapefruit juice activates P-glycoprotein-mediated drug transport. Pharm. Res. 16, 478–485.
Soons PA, Vogels BA, Roosemalen MC, Schoemaker HC, Uchida E, Edgar B, Lundahl J, Cohen AF & Breimer DD (1991): Grapefruit juice and cimetidine inhibit stereoselective metabolism of nitrendipine in humans. Clin. Pharmacol. Ther. 50, 394–403.
Spahn Langguth H & Langguth P (2001): Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol. Eur. J. Pharm. Sci. 12, 361–367.
Spence JD (1997): Drug interactions with grapefruit: whose responsibility is it to warn the public? Clin. Pharmacol. Ther. 61, 395–400.
Takanaga H, Ohnishi A, Matsuo H & Sawada Y (1998): Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit juice components in caco-2 cells. Biol. Pharm. Bull. 21, 1062–1066.
Takanaga H, Ohnishi A, Murakami H, Matsuo H, Higuchi S, Urae A, Irie S, Furuie H, Matsukuma K, Kimura M, Kawano K, Orii Y. Tanaka T & Sawada Y (2000): Relationship between time after intake of grapefruit juice and the effect on pharmacokinetics and pharmacodynamics of nisoldipine in healthy subjects. Clin. Pharmacol. Ther. 67, 201–214.
Talajic M, DeRoode MR & Nattel S (1987): Comparative electrophysiologic effects of intravenous amiodarone and desethylamiodarone in dogs: evidence for clinically relevant activity of the metabolite. Circulation 75, 265–271.
Tian R, Koyabu N, Takanaga H, Matsuo H, Ohtani H & Sawada Y (2002): Effects of grapefruit juice and orange juice on the intestinal efflux of P-glycoprotein substrates. Pharm. Res. 19, 802–809.
Ubeaud G, Hagenbach J, Vandenschrieck S, Jung L & Koffel JC (1999): In vitro inhibition of simvastatin metabolism in rat and human liver by naringenin. Life Sci. 65, 1403–1412.
Uno T, Ohkubo T, Sugawara K, Higashiyama A, Motomura S & Ishizaki T (2000): Effects of grapefruit juice on the stereoselective disposition of nicardipine in humans: evidence for dominant presystemic elimination at the gut site. Eur. J. Clin. Pharmacol. 56, 643–649.
Vanakoski J, Mattila MJ & Seppala T (1996): Grapefruit juice does not enhance the effects of midazolam and triazolam in man. Eur. J. Clin. Pharmacol. 50, 501–508.
Vincent J, Harris SI, Foulds G, Dogolo LC, Willavize S & Friedman HL (2000): Lack of effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of amlodipine. Br. J. Clin. Pharmacol. 50, 455–463.
Wang EJ, Casciano CN, Clement RP & Johnson WW (2001): Inhibition of P-glycoprotein transport function by grapefruit juice psoralen. Pharm. Res. 18, 432–438.
Williams D & Feely J (2002): Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin. Pharmacokinet. 41, 343–370.
Woosley RL, Chen Y, Freiman JP & Gillis RA (1993): Mechanism of the cardiotoxic actions of terfenadine. JAMA 269, 1532–1536.
Yasui N, Kondo T, Furukori H, Kaneko S, Ohkubo T, Uno T, Osanai T, Sugawara K & Otani K (2000): Effects of repeated ingestion of grapefruit juice on the single and multiple oral-dose pharmacokinetics and pharmacodynamics of alprazolam. Psychopharmacology (Berl) 150, 185–190.
Yee GC, Stanley DL, Pessa LJ, Dalla Costa T, Beltz SE, Ruiz J & Lowenthal DT (1995): Effect of grapefruit juice on blood cyclosporin concentration. Lancet 345, 955–956.
Yun CH, Okerholm RA & Guengerich FP (1993): Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation. Drug Metab. Dispos. 21, 403–409.
Zaidenstein R, Dishi V, Gips M, Soback S, Cohen N, Weissgarten J, Blatt A & Golik A (1998): The effect of grapefruit juice on the pharmacokinetics of orally administered verapamil. Eur. J. Clin. Pharmacol. 54, 337–340.
Zhang QY, Dunbar D, Ostrowska A, Zeisloft S, Yang J & Kaminsky LS (1999): Characterization of human small intestinal cytochromes P-450. Drug Metab. Dispos. 27, 804–809.
Zhou L, Chen BP, Kluger J, Fan C & Chow MS (1998): Effects of amiodarone and its active metabolite desethylamiodarone on the ventricular defibrillation threshold. J. Am. Coll. Cardiol. 31, 1672–1678.
About this article
Cite this article
Dahan, A., Altman, H. Food–drug interaction: grapefruit juice augments drug bioavailability—mechanism, extent and relevance. Eur J Clin Nutr 58, 1–9 (2004). https://doi.org/10.1038/sj.ejcn.1601736
This article is cited by
Scientific Reports (2022)
Pharmacokinetic parameters of ifosfamide in mouse pre-administered with grapefruit juice or naringin
Scientific Reports (2019)